Adiponectin–leptin ratio for the early detection of lean non-alcoholic fatty liver disease independent of insulin resistance DOI Creative Commons
Chia‐Wen Lu, Kuen‐Cheh Yang,

Yu‐Chiao Chi

et al.

Annals of Medicine, Journal Year: 2023, Volume and Issue: 55(1), P. 634 - 642

Published: Feb. 15, 2023

Lean Non-alcoholic Fatty Liver Disease (NAFLD) shares a similar disease burden to those of their overweight counterparts and should be detected early. We hypothesized that the adiponectin-leptin ratio (AL ratio) could good marker for early detection lean NAFLD independent insulin resistance.A total 575 adults without diabetes were enrolled in community-based study. The subjects stratified into controls, NAFLD, simple overweight/obesity groups according body mass index (BMI) ultrasonographic fatty liver indicators. Serum adiponectin leptin levels measured by enzyme-linked immunosorbent assay. Multivariate logistic regression analyses performed estimate odds having relation tertiles serum AL concentration after adjustment. Receiver operating characteristic (ROC) applied evaluate diagnostic performance NAFLD.The mean age participants was 42.8 ± 11.5 years. Comparing with highest versus lowest tertile 0.28(95%CI: 0.12-0.69) Putting ratio, BMI, triglyceride, AST/ALT diagnosis ROC 0.85 (95% CI: 0.82-0.88), 0.83 CI 0.78-0.87) 0.86 081-0.91) all women men, respectively. (p < .001).The study revealed biomarker distinguish patients from controls resistance. [AQ3]Key messagesThe prevalence non-alcoholic increases globally is related diseases metabolic dysfunctions. subset early.Adiponectin-leptin associated severity steatosis predictor obese better than each single adipokine. To date, there no investigation explores specifically relationship between ratio.Our found sole regardless resistance NAFLD. Having adjustment age, sex, current smoking, exercise habits, HOMA-IR AST/ALT. (0.85; 95% 0.82-0.88). Further rigorous necessary promptly performed.

Language: Английский

Pharmacotherapy of type 2 diabetes: An update and future directions DOI

Antea DeMarsilis,

Niyoti Reddy,

Chrysoula Boutari

et al.

Metabolism, Journal Year: 2022, Volume and Issue: 137, P. 155332 - 155332

Published: Oct. 12, 2022

Language: Английский

Citations

95
Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges DOI Open Access
Michail Kokkorakis, Chrysoula Boutari, Michael A. Hill

et al.

Metabolism, Journal Year: 2024, Volume and Issue: 154, P. 155835 - 155835

Published: March 19, 2024

Language: Английский

Citations

79
From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need DOI
Michail Kokkorakis, Chrysoula Boutari, Niki Katsiki

et al.

Metabolism, Journal Year: 2023, Volume and Issue: 147, P. 155664 - 155664

Published: July 28, 2023

Language: Английский

Citations

42
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies DOI Open Access
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek

et al.

Pharmacological Reviews, Journal Year: 2024, Volume and Issue: 76(3), P. 454 - 499

Published: Jan. 30, 2024

Steatotic liver disease (SLD) displays a dynamic and complex phenotype. Consequently, the metabolic dysfunction-associated steatotic (MASLD)/metabolic steatohepatitis (MASH) therapeutic pipeline is expanding rapidly in multiple directions. In parallel, non-invasive tools for diagnosing monitoring responses to interventions are being studied, clinically feasible findings explored as primary outcomes interventional trials. The realization that distinct subgroups exist under umbrella of SLD should guide more precise personalized treatment recommendations facilitate advancements pharmacotherapeutics. This review summarizes recent updates pathophysiology-based nomenclature outlines both effective pharmacotherapeutics those MASLD/MASH, detailing their mode action current status phase 2 3 clinical Of extensive arsenal MASLD/MASH pipeline, several have been rejected, whereas other, mainly monotherapy options, shown only marginal benefits now tested part combination therapies, yet others still development monotherapies. Although successful drug candidate (or combinations) remains elusive, such approaches will ideally target MASH fibrosis while improving cardiometabolic risk factors. Due urgent need novel strategies potential availability safety tolerability data, repurposing existing approved drugs an appealing option. Finally, it essential highlight and, by extension, MASLD be recognized approached systemic affecting organs, with vigorous implementation interdisciplinary coordinated plans. Significance Statement SLD, including, among others, MASH, considered most prevalent chronic condition than one-fourth global population. aims provide information regarding pathophysiology, diagnosis, management line guidelines Collectively, hoped provided furthers understanding state direct implications stimulates additional research initiatives.

Language: Английский

Citations

30
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases DOI Creative Commons

Reddemma Sandireddy,

Suganya Sakthivel,

Priyanka Gupta

et al.

Frontiers in Cell and Developmental Biology, Journal Year: 2024, Volume and Issue: 12

Published: July 16, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty (NAFLD), is the most common disorder worldwide, with an estimated global prevalence of more than 31%. steatohepatitis (MASH), formerly (NASH), a progressive form MASLD characterized by hepatic steatosis, inflammation, and fibrosis. This review aims to provide comprehensive analysis extrahepatic manifestations MASH, focusing on chronic diseases related cardiovascular, muscular, renal systems. A systematic published studies literature was conducted summarize findings systemic impacts MASH. The focused association MASH metabolic comorbidities, cardiovascular mortality, sarcopenia, kidney disease. Mechanistic insights into concept lipotoxic inflammatory "spill over" from MASH-affected were also explored. are highly associated (50%-80%) other comorbidities such impaired insulin response, type 2 diabetes, dyslipidemia, hypertriglyceridemia, hypertension. Furthermore, 90% obese patients diabetes have Data suggest that in middle-aged individuals (especially those aged 45-54), independent risk factor for plays crucial role mediating pathological effects observed. Understanding multifaceted impact heart, muscle, early detection stratification. knowledge timely implementing management strategies addressing multi-organ involvement pathogenesis.

Language: Английский

Citations

24
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence DOI
Emir Muzurović, Špela Volčanšek, Karin Zibar

et al.

Journal of Cardiovascular Pharmacology and Therapeutics, Journal Year: 2022, Volume and Issue: 27

Published: Jan. 1, 2022

The obesity pandemic is accompanied by increased risk of developing metabolic syndrome (MetS) and related conditions: non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH), type 2 diabetes mellitus (T2DM) cardiovascular (CV) (CVD). Lifestyle, as well an imbalance energy intake/expenditure, genetic predisposition, epigenetics could lead to a dysmetabolic milieu, which the cornerstone for development cardiometabolic complications. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs promote positive effects on most components “ continuum” consequently help reduce need polypharmacy. In this review, we highlight main pathophysiological mechanisms factors (RFs), that be controlled GLP-1 GIP/GLP-1 independently or through synergism differences in their mode action. We also address evidence use treatment obesity, MetS its conditions (prediabetes, T2DM NAFLD/NASH). conclusion, have already been established T2DM, cardioprotection patients, while appear potential possibly surpass them same indications. However, prevention complex diseases, such NAFLD/NASH other disorders, would benefit from more thorough clinical patient-centered approach. There identify those patients whom component predominates, whether benefits outweigh any harm.

Language: Английский

Citations

51
Ferroptosis, a new pathogenetic mechanism in cardiometabolic diseases and cancer: Is there a role for statin therapy? DOI
Amirhossein Sahebkar,

Zahra Foroutan,

Niki Katsiki

et al.

Metabolism, Journal Year: 2023, Volume and Issue: 146, P. 155659 - 155659

Published: July 11, 2023

Language: Английский

Citations

32
The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials DOI Creative Commons
Cristina Bică, Roxana Adriana Stoica, Teodor Salmen

et al.

Medicina, Journal Year: 2023, Volume and Issue: 59(6), P. 1136 - 1136

Published: June 12, 2023

Type 2 Diabetes Mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) are part of metabolic syndrome share multiple causal associations. Both conditions have an alarmingly increasing incidence lead to complications, which impact on a variety organs systems, such as the kidneys, eyes, nervous cardiovascular or may cause disruptions. Sodium-glucose cotransporter 2-inhibitors (SGLT2-i), antidiabetic class with well-established benefits, its members also been studied for their presumed effects steatosis fibrosis improvement in patients NAFLD steatohepatitis (NASH). The MEDLINE Cochrane databases were searched randomized controlled trials examining efficacy SGLT2-i treatment NAFLD/NASH T2DM. Of originally identified 179 articles, 21 articles included final data analysis. Dapagliflozin, empagliflozin, canagliflozin some most used agents proven treating by addressing/targeting different pathophysiological targets/mechanisms: insulin sensitivity improvement, weight loss, especially visceral fat glucotoxicity, lipotoxicity even chronic inflammation. Despite considerable variability study duration, sample size, diagnostic method, resulted improvements non-invasive markers This systematic review offers encouraging results that place at top therapeutic arsenal diagnosed T2DM NAFLD/NASH.

Language: Английский

Citations

29
Comparative Associations of Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction–Associated Fatty Liver Disease With Coronary Artery Calcification: A Cross-Sectional and Longitudinal Cohort Study DOI Open Access
Ki‐Chul Sung, Tae Kyung Yoo, Mi Yeon Lee

et al.

Arteriosclerosis Thrombosis and Vascular Biology, Journal Year: 2023, Volume and Issue: 43(3), P. 482 - 491

Published: Feb. 2, 2023

In cross-sectional and retrospective cohort studies, we examined comparative associations between nonalcoholic fatty liver disease (NAFLD) metabolic dysfunction-associated (MAFLD) risk of having or developing coronary artery calcification (CAC). Participants who had health examinations 2010 2019 were analyzed. Liver ultrasonography computed tomography used to diagnose CAC. divided into a MAFLD no-MAFLD group then NAFLD no-NAFLD groups. further no (reference), NAFLD-only, MAFLD-only, both Logistic regression modeling was performed. Cox proportional hazard model examine the incident CAC in participants without at baseline least two measurements. analyses, 162 180 included. Compared with either groups, groups associated higher prevalent (NAFLD: adjusted odds ratio [OR], 1.34 [95% CI, 1.29-1.39]; MAFLD: OR, 1.44 1.39-1.48]). Among 4 MAFLD-only strongest association (adjusted 1.60 1.52-1.69]). Conversely, NAFLD-only lower 0.76 0.66-0.87]). longitudinal 34 233 ratio, 1.68 1.43-1.99]; 1.82 1.56-2.13]). these 2.03,[95% 1.62-2.55]). The not independently 0.88 0.44-1.78]) Conclusions: Both are significantly an increased prevalence incidence These tended be stronger for MAFLD.

Language: Английский

Citations

23
Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group DOI Creative Commons
Andrej Janež, Emir Muzurović, Paweł Bogdański

et al.

Diabetes Therapy, Journal Year: 2024, Volume and Issue: 15(9), P. 1865 - 1892

Published: July 11, 2024

The increasing global incidence of obesity and type 2 diabetes mellitus (T2D) underscores the urgency addressing these interconnected health challenges. Obesity enhances genetic environmental influences on T2D, being not only a primary risk factor but also exacerbating its severity. complex mechanisms linking T2D involve adiposity-driven changes in β-cell function, adipose tissue functioning, multi-organ insulin resistance (IR). Early detection tailored treatment are crucial to mitigate future complications. Moreover, personalized early intensified therapy considering presence comorbidities can delay disease progression diminish cardiorenal Employing combination therapies embracing disease-modifying strategy paramount. Clinical trials provide evidence confirming efficacy safety glucagon-like peptide 1 receptor agonists (GLP-1 RAs). Their use is associated with substantial durable body weight reduction, exceeding 15%, improved glucose control which further translate into prevention, possible remission, improvement cardiometabolic factors Therefore, basis clinical experience current evidence, Eastern Southern Europe Diabetes Expert Group recommends personalized, polymodal approach (comprising GLP-1 RAs) individual patient's phenotype optimize therapy. We expect that availability dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) will significantly contribute modern management continuum.

Language: Английский

Citations

11